CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Tsai, Hsiao Chi ^a   Huang, Chun Yin ^b,c   Su, Hong Lin ^a   Tang, Chih Hsin ^c,d,e  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CONNECTIVE TISSUE GROWTH FACTOR; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL XL; SHORT HAIRPIN RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL X;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BONE NEOPLASMS; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BONE NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MAP KINASE SIGNALING SYSTEM; OSTEOSARCOMA; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898622987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090159     Document Type: Article

References (44)

1. Janeway KA, Grier HE (2010) Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11: 670-678.
2. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, et al. (2003) Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 10: 498-507. (Pubitemid 40486912)
3. Brigstock DR, Goldschmeding R, Katsube KI, Lam SC, Lau LF, et al. (2003) Proposal for a unified CCN nomenclature. Molecular pathology: MP 56: 127-128. (Pubitemid 36461474)
4. Perbal B (2004) CCN proteins: multifunctional signalling regulators. Lancet 363: 62-64. (Pubitemid 38076928)
5. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, et al. (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2: e534.
6. Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, et al. (1999) Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18: 1073-1080. (Pubitemid 29086285)
7. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61: 8917-8923. (Pubitemid 34013909)
8. Hou CH, Hsiao YC, Fong YC, Tang CH (2009) Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone 44: 233-242.
9. Kubo M, Kikuchi K, Nashiro K, Kakinuma T, Hayashi N, et al. (1998) Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br J Dermatol 139: 192-197. (Pubitemid 28389390)
10. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK (2011) CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer 105: 231-238.
11. Yin D, Chen W, O'Kelly J, Lu D, Ham M, et al. (2010) Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 127: 2257-2267.
12. Sodek KL, Ringuette MJ, Brown TJ (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 124: 2060-2070.
13. Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, et al. (2000) Expression of connective tissue growth factor in cartilaginous tumors. Cancer 89: 1466-1473.
14. Zuo GW, Kohls CD, He BC, Chen L, Zhang W, et al. (2010) The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 25: 795-806.
15. Schlaepfer DD, Hauck CR, Sieg DJ (1999) Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71: 435-478. (Pubitemid 29156312)
16. Demers MJ, Thibodeau S, Noel D, Fujita N, Tsuruo T, et al. (2009) Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1. Journal of cellular biochemistry 107: 639-654.
17. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284. (Pubitemid 47125967)
18. Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4: 677-685. (Pubitemid 40601850)
19. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589. (Pubitemid 38019195)
20. Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244: 164-171. (Pubitemid 44485888)
21. Huang J, Ni J, Liu K, Yu Y, Xie M, et al. (2012) HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72: 230-238.
22. Chiu YC, Lin CY, Chen CP, Huang KC, Tong KM, et al. (2009) Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1-dependent pathway. J Immunol 183: 2785-2792.
23. Yatomi M, Takiguchi Y, Asaka-Amano Y, Arai M, Tada Y, et al. (2007) Altered gene expression by cisplatin in a human squamous cell lung carcinoma cell line. Anticancer Res 27: 3235-3243. (Pubitemid 47607547)
24. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, et al. (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? European journal of cancer 47: 2431-2445.
25. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R (2009) Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 9: 320-340.
26. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985. (Pubitemid 23267698)
27. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, et al. (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7: 3-18. (Pubitemid 46062402)
28. Wang W, Luo H, Wang A (2006) Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93: 578-584. (Pubitemid 43806994)
29. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, et al. (2006) Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 39: 95-100.
30. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR (2003) Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 29: 379-382. (Pubitemid 36675696)
31. Liang X, Da M, Zhuang Z, Wu W, Wu Z, et al. (2009) Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int 33: 119-124.
32. Huang WC, Chen YJ, Hung MC (2011) Implication of nuclear EGFR in the development of resistance to anticancer therapies. BioMedicine 1: 2-10.
33. Croci S, Landuzzi L, Astolfi A, Nicoletti G, Rosolen A, et al. (2004) Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 64: 1730-1736. (Pubitemid 38428695)
34. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, et al. (2004) Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96: 364-375.
35. Moritani NH, Kubota S, Nishida T, Kawaki H, Kondo S, et al. (2003) Suppressive effect of overexpressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Lett 192: 205-214. (Pubitemid 36369275)
36. Schutze N, Noth U, Schneidereit J, Hendrich C, Jakob F (2005) Differential expression of CCN-family members in primary human bone marrow-derived mesenchymal stem cells during osteogenic, chondrogenic and adipogenic differentiation. Cell Commun Signal 3: 5.
37. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, et al. (2005) Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 128: 9-23. (Pubitemid 40039954)
38. Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, et al. (2009) Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 69: 3482-3491.
39. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
40. Wang ZX, Yang JS, Pan X, Wang JR, Li J, et al. (2010) Functional and biological analysis of Bcl-xL expression in human osteosarcoma. Bone 47: 445-454.
41. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Pilecka I, et al. (2005) Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 43: 237-242. (Pubitemid 41582146)
42. Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5: 65-72. (Pubitemid 35033448)
43. Arnott JA, Lambi AG, Mundy C, Hendesi H, Pixley RA, et al. (2011) The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev Eukaryot Gene Expr 21: 43-69.
44. Spina A, Sorvillo L, Di Maiolo F, Esposito A, D'Auria R, et al. (2013) Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. J Cell Physiol 228: 198-206.